Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARL | Q9H300 | 2/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18522845 | 0.84 | PARL (0.36) | PARLALOX12 | |
| SCHEMBL4955196 | 0.80 | PARL (0.33) | PARL | |
| SCHEMBL8348981 | 0.79 | PARL (0.39) | PARLALOX12ALDH1A1LMNATP53 | |
| SCHEMBL8926844 | 0.75 | ALDH1A1 (0.34) | ALDH1A1TP53 | |
| SCHEMBL7156883 | 0.73 | — | — | |
| SCHEMBL9656768 | 0.73 | — | — | |
| SCHEMBL21827564 | 0.73 | — | — | |
| SCHEMBL16015094 | 0.73 | — | — | |
| SCHEMBL784740 | 0.73 | — | — | |
| SCHEMBL14624382 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389298-B2 | Methods using novel chemiluminescent labels | LUMIGEN, INC. (US) | 2013-03-05 | — | — | US | claimed |
| US-20100190271-A1 | METHODS USING NOVEL CHEMILUMINESCENT LABELS | LUMIGEN, INC. (US) | 2010-07-29 | — | — | US | claimed |
| US-20100173429-A1 | METHODS USING NOVEL CHEMILUMINESCENT LABELS | LUMIGEN, INC. (US) | 2010-07-08 | — | — | US | claimed |
| US-20080113924-A1 | Neuramindase Inhibitor | NATIONAL INSTITUE OF ADVANCE INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2008-05-15 | — | — | US | claimed |
| US-7288264-B1 | Contact-killing antimicrobial devices | SURFACINE DEVELOPMENT COMPANY, L.L.C. (US) | 2007-10-30 | — | — | US | claimed |
| US-20070172878-A1 | Methods using novel chemiluminescent labels | LUMIGEN, INC. | 2007-07-26 | — | — | US | claimed |
| US-20060205094-A1 | Methods using novel chemiluminescent labels | LUMIGEN, INC. | 2006-09-14 | — | — | US | claimed |
| EP-0644778-B1 | TECHNETIUM-99m LABELED PEPTIDES FOR IMAGING | DIATIDE INC (US) | 1997-05-14 | — | — | EP | claimed |
| US-4937007-A | Process for inhibiting the deposit of paraffins in crude oils and petroleum sections utilizing N-substituted succinimide ethers | SOCIETE NATIONALE ELF AQUITAINE (FR) | 1990-06-26 | — | — | US | claimed |
| US-4816390-A | MONOCLONAL OR POLYCLONAL ANTIBODIES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1989-03-28 | — | — | US | claimed |
| US-12359115-B2 | Method of treating a subsurface formation with a coated proppant | SAUDI ARABIAN OIL COMPANY (SA) | 2025-07-15 | — | — | US | disclosed |
| US-12325825-B2 | Composition for a coated proppant | SAUDI ARABIAN OIL COMPANY (SA) | 2025-06-10 | — | — | US | disclosed |
| US-20240392181-A1 | COMPOSITION FOR A COATED PROPPANT | SAUDI ARABIAN OIL COMPANY (SA) | 2024-11-28 | — | — | US | disclosed |
| US-20240392180-A1 | METHOD OF TREATING A SUBSURFACE FORMATION WITH A COATED PROPPANT | SAUDI ARABIAN OIL COMPANY (SA) | 2024-11-28 | — | — | US | disclosed |
| US-RE49466-E1 | Solution phase homogeneous assays | BECKMAN COULTER, INC. (US) | 2023-03-21 | — | — | US | disclosed |
| US-4937007-A | Process for inhibiting the deposit of paraffins in crude oils and petroleum sections utilizing N-substituted succinimide ethers | SOCIETE NATIONALE ELF AQUITAINE (FR) | 1990-06-26 | — | — | US | disclosed |
| US-4937007-A | Process for inhibiting the deposit of paraffins in crude oils and petroleum sections utilizing N-substituted succinimide ethers | SOCIETE NATIONALE ELF AQUITAINE (FR) | 1990-06-26 | — | — | US | disclosed |
| US-4937007-A | Process for inhibiting the deposit of paraffins in crude oils and petroleum sections utilizing N-substituted succinimide ethers | SOCIETE NATIONALE ELF AQUITAINE (FR) | 1990-06-26 | — | — | US | disclosed |
| EP-0212673-A2 | Photographic paper | FUJI PHOTO FILM CO., LTD. (JP) | 1987-03-04 | — | — | EP | disclosed |
| US-4194982-A | ANTIDEPOSIT AGENT, OIL ADDITIVE | TEXACO INC. (US) | 1980-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113924-A1 | Neuramindase Inhibitor | NMBR, NEU1, NMUR1 | PARL 2809/4885ALOX12 3335/4885ALDH1A1 1007/4885 |
| US-20070172878-A1 | Methods using novel chemiluminescent labels | HLCS, LANCL1, ACR | PARL 3319/4885ALOX12 1178/4885ALDH1A1 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.